Neurocrine Biosciences (NBIX) Receivables (2010 - 2026)

Neurocrine Biosciences has reported Receivables for 17 years, with the latest figure at $768.1 million in Q1 2026.

• For the quarter ending Q1 2026, Receivables rose 48.86% year-over-year to $768.1 million; the trailing twelve-month figure through Mar 2026 stood at $768.1 million (up 48.86% YoY), and the FY2025 full-year result was $707.3 million, up 43.32% from the prior year.
• Receivables for Q1 2026 stood at $768.1 million, up from $707.3 million in the prior quarter.
• The five-year high for Receivables was $768.1 million in Q1 2026, with the low at $266.5 million in Q1 2022.
• Historically, Receivables has averaged $476.2 million across 5 years, with a median of $463.3 million in 2024.
• Annual changes were most pronounced in 2022 — Receivables soared 88.97% — and 2024, when it increased 9.54%.
• Neurocrine Biosciences' Receivables stood at $354.7 million in 2022, then rose by 27.01% to $450.5 million in 2023, then advanced by 9.54% to $493.5 million in 2024, then jumped by 43.32% to $707.3 million in 2025, then rose by 8.6% to $768.1 million in 2026.
• The last three Receivables figures came in at $768.1 million (Q1 2026), $707.3 million (Q4 2025), and $728.0 million (Q3 2025), per Business Quant data.